Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer
Authors: Lisa M. Jacola, Marita Partanen, Jurgen Lemiere, Melissa M. Hudson, Sophie Thomas
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Neurocognitive Outcomes in Survivors of Pediatric Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.02444 Journal of Clinical Oncology - published online before print April 22, 2021 PMID: 33886364 Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer Lisa M. Jacola , PhD1xLisa M. JacolaSearch for articles by this author; Marita Partanen , PhD2xMarita PartanenSearch for articles by this author; Jurgen Lemiere , PhD3xJurgen LemiereSearch for articles by this author; Melissa M. Hudson , MD1xMelissa M. HudsonSearch for articles by this author; and Sophie Thomas , PhD4xSophie ThomasSearch for articles by this author Show More 1St Jude Children's Research Hospital, Memphis, TN2Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands3University Hospital Leuven, Leuven, Belgium4Nottingham Children's Hospital, Nottingham, United Kingdom https://doi.org/10.1200/JCO.20.02444 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveWe present a tiered model of neuropsychological care for childhood cancer survivors.Knowledge GeneratedThe Psychosocial Standards of Care Project for Childhood Cancer guidelines highlight the need for systematic and interdisciplinary neurocognitive assessment that begins during treatment. This approach emphasizes feasibility in settings with varying resources and among culturally diverse patients and families, while maintaining a high level of service quality.RelevanceNeurocognitive late effects are common and life-altering sequelae of childhood cancer, which have potential adverse effects on educational and vocational attainment, and social integration. Regular monitoring of neurocognitive functioning can facilitate early detection of problems and early intervention to improve quality of life. The developmental perspective of this model is crucial because neurotoxic agents and/or treatment complications can have an adverse and longstanding impact on developing neural systems.SUPPORTSupport was provided by the NIH National Cancer Institute grants(s) (P30-CA21765 and GM92666 to St Jude Children's Research Hospital) and the American Lebanese Syrian Associated Charities (ALSAC).AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAssessment and Monitoring of Neurocognitive Function in Pediatric CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jurgen LemiereEmployment: CovanceMelissa M. HudsonConsulting or Advisory Role: Oncology Research Information Exchange Network, Princess Máxima CenterSophie ThomasLeadership: Dr Sophie Thomas Clinical Psychologist LtdNo other potential conflicts of interest were reported.